Drug profile · INN
insulin degludec
RYZODEG
insulin degludec (RYZODEG) is a insulin receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Drug details — insulin degludec
- US status
- approved
- Class
- Alimentary tract and metabolism (A10)
- Route
- SUBCUTANEOUS
- Patents
- 0
- Programs
- 9
- Data quality
- 0.84
Quick answer
insulin degludec (RYZODEG) is a insulin receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Mechanism of action
Insulin receptor agonist
Primary target: Insulin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is insulin degludec?
insulin degludec (RYZODEG) is a insulin receptor agonist. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for insulin degludec?
RYZODEG is a marketed brand name for insulin degludec. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin degludec?
insulin degludec has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.